دورية أكاديمية
أعرض في EDS

Repurposing colchicine's journey in view of drug-to-drug interactions. A review.

التفاصيل البيبلوغرافية
العنوان: Repurposing colchicine's journey in view of drug-to-drug interactions. A review.
المؤلفون: Vrachatis DA; 2nd Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece., Papathanasiou KA; 2nd Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece., Giotaki SG; 2nd Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece., Iliodromitis KE; Evangelisches Krankenhaus Hagen-Haspe, Clinic for Cardiology and Electrophysiology, Germany., Papaioannou TG; First Department of Cardiology, Medical School, National and Kapodistrian University of Athens, Greece.; Department of History of Medicine and Medical Ethics, Medical School, National and Kapodistrian University of Athens, Greece., Stefanini GG; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy., Cleman M; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Siasos G; 3rd Department of Cardiology, 'Sotiria Hospital', National and Kapodistrian University of Athens, Athens, Greece., Reimers B; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy., Lansky A; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Tardif JC; Montreal Heart Institute Montreal, University of Montreal, Montreal, Canada., Deftereos SG; 2nd Department of Cardiology, National and Kapodistrian University of Athens, Athens, Greece., Giannopoulos G; Department of Cardiology, General Hospital of Athens 'G.Gennimatas', Athens, Greece.
المصدر: Toxicology reports [Toxicol Rep] 2021 Jul 09; Vol. 8, pp. 1389-1393. Date of Electronic Publication: 2021 Jul 09 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ireland Ltd Country of Publication: Ireland NLM ID: 101630272 Publication Model: eCollection Cited Medium: Internet ISSN: 2214-7500 (Electronic) Linking ISSN: 22147500 NLM ISO Abbreviation: Toxicol Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Ireland] : Elsevier Ireland Ltd., [2014]-
مستخلص: Colchicine's medical evolution is historically bound to the Mediterranean basin, since remarkable researchers from this region underscored its valuable properties. With the passing of years colchicine became an essential pharmaceutical substance for the treatment of rheumatologic and cardiovascular diseases. In light of recent findings, the therapeutic value of colchicine has grown. In clinical practice, colchicine remains underutilized in view of its proven efficacy and safety. Its complex pharmacokinetics and multifaceted anti-inflammatory role remain under investigation. The current review addresses the safe administration of colchicine in view of key drug to drug interactions. Finally, we are briefly presenting colchicine's future potential applications.
Competing Interests: The authors report no declarations of interest.
(© 2021 Published by Elsevier B.V.)
References: J Am Coll Cardiol. 2012 Oct 30;60(18):1790-6. (PMID: 23040570)
Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. (PMID: 20222053)
Curr Cardiol Rep. 2018 Jun 14;20(8):62. (PMID: 29904810)
Psychiatriki. 2019 Jan-Mar;30(1):58-65. (PMID: 31115355)
J Stroke Cerebrovasc Dis. 2020 May;29(5):104756. (PMID: 32160956)
Inflammation. 2016 Feb;39(1):182-189. (PMID: 26318864)
Eur Heart J. 2020 Nov 7;41(42):4092-4099. (PMID: 32860034)
Intern Emerg Med. 2021 Mar;16(2):487-496. (PMID: 33400158)
Xenobiotica. 2005 Jul;35(7):737-53. (PMID: 16316932)
J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. (PMID: 23265346)
Eur J Neurol. 2020 Jun;27(6):1035-1038. (PMID: 32134555)
Hellenic J Cardiol. 2021 Jan 6;:. (PMID: 33421583)
Curr Pharm Des. 2018;24(6):659-663. (PMID: 29359661)
Am J Ther. 2014 Jan-Feb;21(1):2-9. (PMID: 24401702)
Semin Arthritis Rheum. 2015 Dec;45(3):341-50. (PMID: 26228647)
Arthritis Res Ther. 2020 Feb 13;22(1):28. (PMID: 32054504)
J Cell Mol Med. 2016 Jun;20(6):1182-90. (PMID: 26928894)
Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):14-23. (PMID: 23286287)
Eur J Med Chem. 2018 Apr 25;150:591-600. (PMID: 29550732)
Lancet Respir Med. 2021 May 27;:. (PMID: 34051877)
Toxicol Rep. 2018 Oct 06;5:1107-1113. (PMID: 30450285)
Am J Cardiovasc Drugs. 2017 Oct;17(5):347-360. (PMID: 28353024)
N Engl J Med. 2019 Dec 26;381(26):2497-2505. (PMID: 31733140)
JAMA Cardiol. 2020 Sep 1;5(9):1069-1070. (PMID: 32936267)
Nat Rev Mol Cell Biol. 2018 May;19(5):313-326. (PMID: 29410531)
Circulation. 2016 Nov 22;134(21):e468-e495. (PMID: 27754879)
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):255. (PMID: 32337546)
Eur Heart J. 2017 Jun 7;38(22):1706-1709. (PMID: 30052886)
Hellenic J Cardiol. 2020 Jan - Feb;61(1):42-45. (PMID: 32251729)
J Am Coll Cardiol. 2013 Apr 23;61(16):1679-85. (PMID: 23500260)
J Cardiol. 2021 Jun;77(6):576-582. (PMID: 33272780)
Arthritis Rheum. 2011 Aug;63(8):2226-37. (PMID: 21480191)
Heart Rhythm. 2014 Apr;11(4):620-8. (PMID: 24508207)
J Neurol Neurosurg Psychiatry. 1996 Apr;60(4):427. (PMID: 8774409)
Circulation. 2015 Oct 13;132(15):1395-403. (PMID: 26265659)
Curr Pharm Des. 2018;24(6):654-658. (PMID: 29336251)
Heart. 2016 Jul 1;102(13):995-1002. (PMID: 26993138)
Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i4-i11. (PMID: 29272515)
Am J Med. 2017 May;130(5):583-587. (PMID: 28065770)
J Cardiovasc Med (Hagerstown). 2021 Aug 1;22(8):637-644. (PMID: 33399344)
J Am Coll Cardiol. 2013 Nov 12;62(20):1817-25. (PMID: 24036026)
Can J Cardiol. 2021 May;37(5):776-785. (PMID: 33075455)
Curr Pharm Des. 2018;24(6):648-653. (PMID: 29336250)
JAMA Netw Open. 2020 Jun 1;3(6):e2013136. (PMID: 32579195)
J Am Soc Nephrol. 1996 Apr;7(4):594-601. (PMID: 8724893)
Rheumatology (Oxford). 2018 Feb 1;57(2):382-387. (PMID: 29029311)
Curr Pharm Des. 2018;24(6):647. (PMID: 29768995)
J Surg Res. 2008 May 15;146(2):184-9. (PMID: 17597159)
AAPS J. 2017 Mar;19(2):409-420. (PMID: 28028729)
Curr Pharm Des. 2018;24(6):690-694. (PMID: 29336247)
Biochem Pharmacol. 2004 Jan 15;67(2):285-92. (PMID: 14698041)
Clin Ther. 2019 Jan;41(1):21-29. (PMID: 30217592)
Eur Heart J. 2021 Jul 21;42(28):2802. (PMID: 33480985)
Arthritis Res Ther. 2006;8 Suppl 1:S1. (PMID: 16820040)
Rheumatol Int. 2020 Nov;40(11):1741-1751. (PMID: 32880032)
Life Sci. 2010 Jan 2;86(1-2):52-8. (PMID: 19914261)
معلومات مُعتمدة: UL1 TR001863 United States TR NCATS NIH HHS
فهرسة مساهمة: Keywords: ACS, acute coronary syndrome; CAD, coronary artery disease; COVID-19, coronavirus disease - 19; Colchicine; DOACs, direct oral anticoagulants; History; Inflammation; Lp-PLA2, Lipoprotein-associated phospholipase A2; NLRP3, NOD-, LRR- and pyrin domain-containing protein 3; Pharmacokinetics; ROCK, Rho-associated protein kinase; Repurposing; Safety; eGFR, estimated glomerular filtration rate
تواريخ الأحداث: Date Created: 20210721 Latest Revision: 20210920
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8280530
DOI: 10.1016/j.toxrep.2021.07.009
PMID: 34285885
قاعدة البيانات: MEDLINE
الوصف
تدمد:2214-7500
DOI:10.1016/j.toxrep.2021.07.009